Investor service announcement no. 4/2014
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 3 June 2014
Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus® XR (tacrolimus extended-release tablets)
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S. commercialization of Envarsus® XR (tacrolimus extended-release tablets) an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients.
William Polvino, chief executive officer of Veloxis, said, “The relatively small and concentrated organ transplant market in the U.S. enables Veloxis to retain all of the economics of Envarsus XR with a manageable sales and marketing investment. The expanded management team and newly organized management structure is part of that process as we prepare for the potential U.S. launch of Envarsus XR if approved by FDA later this year. We have assembled a strong senior team with considerable talent and depth of experience. We look forward to potential regulatory approvals for Envarsus XR in the U.S. and E.U. We believe that Envarsus XR represents an important potential therapeutic option to transplant recipients and we have begun assembling the talent required to support the product, the physician community, and transplant patients.”
For Investor and media contact:
John Weinberg, M.D. Johnny Stilou
EVP & COO EVP & CFO
Phone: +1 732 321 3208 Phone: + 45 21 227 227
About Envarsus® XR and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. Envarsus® is an investigational drug that is being developed as a once‐daily tablet version of tacrolimus, with improved bioavailability, consistent pharmacokinetic performance and reduced peak‐to‐trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® XR for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through Salix, Inc.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Logo